Three-Drug cocktail aims to tame transplant complications in blood cancer patients
NCT ID NCT07675174
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This trial investigates whether adding bortezomib and sitagliptin to standard post-transplant cyclophosphamide can prevent graft-versus-host disease (GvHD) in adults with blood cancers receiving a stem cell transplant. Participants receive the drug combination after transplant, with doses adjusted for safety. The study aims to find the best dose and measure how well it prevents acute GvHD within the first 100 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cyclophosphamide, bortezomib, and sitagliptin
- What this could lead to
- If successful, this combination could reduce the risk of severe graft-versus-host disease, making stem cell transplants safer for blood cancer patients.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not apply broadly. The drugs may cause side effects or fail to prevent GvHD effectively.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Northwell Health
New Hyde Park, New York, 11040, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can trained immune cells stop blood cancer relapse?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?